AI: The Next Revolution In Medicine?

Jan 23, 2019

AI: The Next Revolution In Medicine?

Tagged:

Watch our CEO, Joanna Shields, as she takes the stage and returns to DLD 2019 - an event which is a source of great inspiration and hope.

Given the state of the world today, at BenevolentAI we think we could all benefit from a giant dose of optimism. We believe that unconventional thinking combined with purposeful technology can truly change outcomes in the world. And that is what Joanna touches upon during her talk to the audience at DLD.

More Posts

You Might Also Like

AI in Drug Discovery

This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.

Jul 13, 2021

BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman

Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.

Jul 9, 2021

Product design in AI-drug discovery: how to design products for and with scientific users

User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.

Jul 6, 2021

Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis

Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.

May 5, 2021

A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF

Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.

Apr 23, 2021

Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population

Apr 8, 2021